NCT06866158Active, not recruitingPhase 1/2
Autologous Dendritic Cell as Adjunct Therapy for Diabetic Kidney Disease
Single-arm Open-label Clinical Trial: Autologous Dendritic Cells and Lymphocytes in Type 2 Diabetes Mellitus With Albuminuria
Source: ClinicalTrials.gov · Last updated 5 Dec 2025
Brief summary (registry, in English)
The goal of this single-arm, open-label clinical trial is to evaluate the effects of subcutaneous autologous dendritic cell (DC) and lymphocyte administration on albuminuria and endothelial dysfunction in Type 2 Diabetes Mellitus (T2DM) patients with Diabetic Kidney Disease (DKD). The main questions it aims to answer are: * Does autologous DC immunotherapy reduce urine albumin-creatinine ratio (UACR) in DKD patients? * What are the underlying mechanisms (modulation of inflammation, endothelial dysfunction, angiogenesis, fibrosis, and structural changes) through which DC immunotherapy reduces UACR in DKD patients? Participants will: * Undergo collection of autologous dendritic cells, which will be matured ex vivo using SARS-CoV-2 S protein. * Receive a single subcutaneous injection consisting of matured dendritic cells and lymphocyte reinfusion. * Have UACR measured at baseline and at weeks 1, 2, 3, and 4 post-immunotherapy. * Undergo assessments of other laboratory parameters and kidney imaging (ultrasonography and/or magnetic resonance imaging) at baseline and week 4 post-treatment. * What is the effect of autologous DC immunotherapy on knee OA, assessed by radiographic changes (x-ray) and patient-reported outcomes (WOMAC score)? Additionally, a subgroup of subjects who had neuropathy as comorbidity will be assessed using Electromyography (EMG) and the Toronto Clinical Neuropathy Scale (TCNS). These assessments aimed to determine the impact of the intervention on peripheral nerve function, clinical neuropathy symptoms over the study period. Another subgroup of subjects who had knee osteoarthritis will be assessed their knee x-ray and Western Ontario and McMaster Universities osteoarthritis index (WOMAC) score. These assessments aimed to determine the impact of the intervention on knee anatomic structure, function, and pain.
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 1/2
- Study type
- Interventional
- Enrollment
- 80 (actual)
- First submitted
- 22 Feb 2025
- Start date
- 1 May 2024
- Primary completion date
- 5 Aug 2024
- Lead sponsor
- PT. JES Kasih Nusantara Sejahterah
- Diseases
- Chronic kidney disease, Type 2 diabetes
- NCT number
- NCT06866158
What you commit to
- Study type: Interventional · Phase 1/2
- Participants enrolled: 80
- From 1 May 2024 to the primary completion date, 5 Aug 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Receiving immunosuppressive treatments such as corticosteroids, hydroxychloroquine, methotrexate, cyclophosphamide, and others within the last 4 weeks.
- Diagnosed with invasive cancer and currently receiving anti-cancer therapy, except for hormonal therapy for breast or prostate cancer.
- History of thromboembolism or a genetic predisposition to thromboembolism, or currently on anti-thromboembolic therapy other than low-dose aspirin.
Other illness
- Known to have other kidney diseases (e.g., polycystic kidney disease, lupus nephritis, ANCA-associated vasculitis, etc.).
- Known to have other conditions that can cause albuminuria (e.g., myeloma, rhabdomyolysis, paroxysmal nocturnal hemoglobinuria, orthostatic albuminuria, etc.).
- Diagnosed with other types of diabetes (Type 1 DM, gestational DM, or other forms of DM).
- Known to have immunodeficiency diseases such as human immunodeficiency virus (HIV), hepatitis C virus (HCV), or hepatitis B virus (HBV); no blood testing required.
- In the investigator's judgment, any illness or medical condition that may hinder the subject's participation, including acute, subacute, intermittent, or chronic diseases that could place the subject at risk of injury, prevent compliance with the study protocol, or interfere with study assessments.
- Measurable parameters include:
- Severe obesity: BMI \> 40
- Uncontrolled hypertension: systolic \>180 mmHg, diastolic \>100 mmHg
Other
- Positive pregnancy test.
- Requires oxygen supplementation.
- Physical or mental disabilities preventing normal daily activities.
- Unwilling to sign the written informed consent.
Who the study is looking for
- Male or female over 18 years old
- Understands and agrees to comply with study procedures by providing written informed consent.
- In the investigator's judgment, the subject is able and willing to comply with study procedures.
- In the investigator's judgment, the subject is in generally good physical and mental health. This includes the following factors:
- Age \> 65 years
- Mild to moderate obesity (BMI 30 to 40)
- Controlled hypertension with medication
- Controlled hyperlipidemia with medication
- Mild chronic lung disease
- Previously diagnosed with cancer and in remission for at least 1 year
- Meets the diagnostic criteria for Type 2 Diabetes Mellitus (DM) according to Indonesia's Endocrinology Society (PERKENI) 2021.
- eGFR ≥ 30 mL/min/1.73 m².
- Urinary albumin-creatinine ratio (UACR) ≥ 30 mg/g.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Gatot Soebroto Central Army Hospital Coordinator of this site? Confirm its status | Jakarta Pusat | Indonesia | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.